home   about   contact   links
MPT WWW
 
 

December 11, 2007

The View From the Top...

... is always top-down, particularly in that city of the exalted, Washington D.C. So what is it this time? "A Food and Drug Administration medical reviewer said it wasn't clear if consumers could safely and effectively use a proposed Merck & Co. cholesterol-lowering drug without a prescription." (Wall Street Journal, December 11)

And that just about sums it all up, doesn't it? Forget consultations between doctors and their patients. Forget the heterogeneous characteristics and needs of millions of individual patients. Forget the huge informational advantage engendered by ongoing experience, modern mass communication, and individual trial and error. Forget the reality that some very substantial proportion of prescriptions are for off-label uses. Sorry: The Beltway knows best, children---because it says so---and "safety and effectiveness" is one-size-fits-all.

It is not only inside the Beltway that this sort of arrogance is to be found, but it is the Beltway in which it is rewarded so consistently and in which it simply is more than a way of life. It is a mindset.

Posted by Benjamin Zycher at December 11, 2007 02:00 PM

Comments

Post a comment




Remember Me?


PRINT PAGE | EMAIL PAGE
 
IN THE SPOTLIGHT:
Drug Development Needs Private Industry
by Benjamin Zycher, Ph.D.
June 28, 2008

FORUM

COMMENTARY

RESEARCH

Medical Progress

Intellectual Property
Rights & Innovation

Global Health & Bio-terrorism

Prescriptions for Policy

  
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org